- Target Boycott Shouldn't Worry Investors: It Won't Hurt Sales; Target Responds
- Sarepta Can Win Speedy FDA Drug Approval
- 10 Fuel-Efficient Cars For Your Volkswagen Diesel Buyback Money
- 10 Countries Where That Social Security Check Will Let You Retire in Style
- Retirees Are Opting to Rent Homes Likes Millennials
The Budweiser maker says it's prepared to sell all its target's breweries in central and eastern Europe as it works to complete its $105 billion takeover in the second half.
Mergers and acquisitions are taking an eternity to close, thanks to extra scrutiny from government regulators.
The takeover deal for the cardiovascular devices specialist come less than three months after Abbott's $8.4 billion agreement to buy Alere.
Thursday's parade of deals seem to answer a question that's been bugging health care investors for most of 2016: why haven't retreating biotech valuations sparked an uptick in M&A activity?
The FTC's competition director Deborah Feinstein says the antitrust agencies' tough stand on mergers today is a result of companies pushing the legal limits.
Former DOJ official William Kolasky has seen both sides of the regulation game. We talked with him about the evolution of merger enforcement and today's hardcore regulators.
Universal Health Services reported a 7.8% increase in acute care same facility adjusted admissions during the first quarter.
The Federal Reserve has been on a roll approving regional bank acquisitions with more to come, even as the Department of Justice is cracking down on mergers.
Jim Cramer expects to see more deal activity in the pharmaceuticals space.
A $35 billion dollar deal that would change the oil and gas industry forever hangs in the balance as an aggressive DOJ takes action. Will the Halliburton-Baker Hughes deal survive?
Mergers are getting more complex and the government is struggling to keep up. The pace of regulatory review has slowed to a crawl.
Every administration since Reagan has gotten tougher on mergers. Obama tops them all. Using data from the FTC, TheStreet has discovered how big government is flexing its antitrust muscles.
Jim Cramer says there is a risk that the Dow Chemical and DuPont deal gets blocked on antitrust concerns.
Jim Cramer is bullish on Abbott Laboratories' acquisition of St. Jude Medical.
U.S. stocks dropped on Thursday, as first quarter gross domestic product came in weaker than expected.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.